A Phase 2 interventional study of paclitaxel and Cisplatin 50mg/m2 in Cervical Cancer, sponsored by Korean Gynecologic Oncology Group. Status unknown at 1 site in Korea, Republic of. Open to female participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2011-12-07.
Sponsored by Korean Gynecologic Oncology Group · Phase 2, Interventional, and Treatment
Purpose Primary endpoint
1,881 studies on the registry are indexed under Uterine Cervical Neoplasms; 567 are open to participants now.
This study's planned enrollment of 69 is below the median of 100 across 1,377 interventional studies indexed under Uterine Cervical Neoplasms.
Browse Uterine Cervical Neoplasms studies →Korean Gynecologic Oncology Group is the lead sponsor of 7 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Paclitaxel 175 mg/m2 over 3 hr Repeat every 3 weeks \* 6 cycles
Cisplatin 50mg/m2 Repeat every 3 weeks \* 6 cycles
Also known as: Cisplatin
Kaplan-Meier
log-rank test Cox regression analysis
This study is status unknown, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Korean Gynecologic Oncology Group